Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

1.8K
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
1.8K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

737
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
737
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

608
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
608
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

2.5K
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

646
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
646
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

562
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
562

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factors associated with Fournier's gangrene survival in a diverse urban community: a 15-year review.

BJU international·2025
Same author

An Actual Use Study of Tamsulosin in Men with Bothersome Urinary Symptoms in a Simulated Over-the-Counter Setting.

Urology practice·2023
Same author

Over-the-Counter Tamsulosin for Men with Urinary Symptoms: A Simulated Self-Selection Study.

Urology practice·2023
Same author

Are Over-the-Counter Alpha Blockers in the Best Interest of Men with Lower Urinary Tract Symptoms?

Urology practice·2023
Same author

Characteristics of men with untreated LUTS interested in over-the-counter tamsulosin.

The Canadian journal of urology·2019
Same author

Is Dipstick Urinalysis Screening Beneficial in Men with Lower Urinary Tract Symptoms?

Advances in therapy·2019
Same journal

Smarter, Not More: The Rationale for Reducing Systematic Cores in the MRI-Targeted Biopsy Era.

The Canadian journal of urology·2026
Same journal

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same journal

Electroacupuncture for sperm improvement in varicocele: a case report.

The Canadian journal of urology·2026
Same journal

Transperineal approach for penetrating injury of corpus spongiosum and bulbous urethra caused by vesicourethral foreign body: a case report.

The Canadian journal of urology·2026
Same journal

Penile fracture and concomitant severe urethral trauma-a case report and discussion of surgical approach.

The Canadian journal of urology·2026
Same journal

Management of retained bullet fragments from posterior urethra after gunshot wound: a case report.

The Canadian journal of urology·2026
See all related articles

Related Experiment Video

Updated: Mar 31, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K

Complementary and alternative medications for benign prostatic hyperplasia.

Aryeh Keehn1, Franklin C Lowe

  • 1Department of Urology, Albert Einstein College of Medicine, Bronx, New York, USA.

The Canadian Journal of Urology
|October 27, 2015
PubMed
Summary
This summary is machine-generated.

Phytotherapy offers no significant benefit for benign prostatic hyperplasia (BPH) symptoms compared to placebo, though it is generally safe. Mild BPH patients may consider it, but those with moderate to severe symptoms should avoid these treatments.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

26.3K

Related Experiment Videos

Last Updated: Mar 31, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate HoLEP.

Published on: March 6, 2018

17.8K
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

20.5K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

26.3K

Area of Science:

  • Urology
  • Pharmacology
  • Integrative Medicine

Background:

  • Complementary and alternative medications (CAM) represent a significant market, particularly for benign prostatic hyperplasia (BPH) management in Europe.
  • Practicing urologists require knowledge of phytotherapeutic agents, their mechanisms, supporting research, and safety profiles due to increasing patient interest.

Purpose of the Study:

  • To review the scientific literature on phytotherapeutic agents used for benign prostatic hyperplasia (BPH).
  • To evaluate the efficacy and safety of selected phytotherapies for BPH management.

Main Methods:

  • A comprehensive literature search identified studies on alternative and complementary treatments for BPH.
  • Selected treatments with adequate clinical data, including Serenoa repens, Pygeum africanum, and Secale cereale, underwent in-depth review.

Main Results:

  • Clinical trials for individual phytotherapeutic agents yielded mixed results.
  • Larger, well-designed studies indicated no significant therapeutic benefit of phytotherapy for BPH symptoms.

Conclusions:

  • Available evidence does not support phytotherapy as a significant treatment for BPH symptoms over placebo, despite a favorable safety profile.
  • Patients with mild BPH reluctant to use standard medications may consider phytotherapy with awareness of its limitations.
  • Phytotherapy is not recommended for patients with moderate to severe BPH.